Navigation Links
Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma

BERKELEY, Calif., March 2 /PRNewswire/ -- Aerovance Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

Study initiation begins today in the United States for AeroTrial, a double-blind, randomized, placebo-controlled, Phase IIb dose-ranging study. Aerovance expects to enroll approximately 500 patients with moderate to severe asthma, in the United States and Europe, who are poorly controlled by the combination of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA). Patients will be randomly assigned to receive one of three Aerovant doses (1 mg, 3 mg or 10 mg) or placebo by inhalation twice daily for 12 weeks, during which time their standard ICS and LABA therapies will be gradually withdrawn. The primary endpoint is exacerbation incidence on Aerovant therapy as compared to placebo. Secondary endpoints include pulmonary function, time to exacerbation, daily peak expiratory flow (PEF) and symptom scores, immunoglobulin E (IgE) levels, and fractional concentration of expired nitric oxide (FeNO).

"Regulatory clearance and initiation of AeroTrial are significant milestones for Aerovance and potentially for patients living with uncontrolled asthma. The efficacy and safety data from our completed Aerovant studies are promising, and we are pleased to begin evaluation of this compound in a large number of moderate to severe asthmatics," said Mark Perry, Aerovance's president and chief executive officer. "Aerovant targets a root cause of asthma by blocking the signaling activity of two key cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), critical in the progression of the disease. Our Phase IIa data suggest that targeted delivery to the lung is superior to systemic administration in blocking the asthmatic activities of IL-4 and IL-13 and has the potential to provide a breakthrough treatment for a patient population with few options."

AeroTrial is a late-stage clinical study using a dry powder formulation and follows positive clinical data from two Phase IIa studies in which Aerovant demonstrated significant benefit in asthmatics who were experimentally challenged with inhaled allergen (The Lancet 2007, 370: 1422-31). The dry powder formulation that will be used in AeroTrial was well tolerated in a recently completed Phase I study in asthmatics. By using a medication based on a protein occurring naturally in the body, AeroTrial seeks a non-steroidal solution to getting control of asthma. For more information, visit

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of the alpha subunit of the IL-4 receptor (IL-4R alpha), a shared component of both the IL-4 and IL-13 receptor complexes. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, California-based biopharmaceutical company focused on the development and commercialization of first-in-class therapies for the treatment of respiratory and inflammatory diseases. For more information, visit

Contact: Andreas Marathovouniotis or David Schull

Russo Partners

212-845-4235 or 212-845-4271

Dave Happel

Aerovance Inc.


SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Show Aerovances Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015 Health Gorilla ( ... Clinical Network – a secure platform for clinical data ... patients interact about and manage healthcare in the US. The ... round, for a combined total of $4.4M raised to date, ... from True Ventures , Harris Barton , ...
(Date:10/13/2015)... -- Research and Markets ( ) has announced ... Cosmetics Packaging - Market Opportunities and Forecasts, 2014 - ... --> --> The anti-counterfeit pharmaceutical ... of 15.7% during 2015-2020 --> ... for about 52% share in 2014 and would continue ...
(Date:10/12/2015)... the United States . By early next year, ... the United States . By early next year, ... The University of Texas MD Anderson Cancer Center, Elekta and ... Tesla) MRI-guided linear accelerator in the United States ... a non-clinical capacity. Royal Philips (NYSE: PHG ...
Breaking Medicine Technology:
(Date:10/13/2015)... PLAINSBORO, N.J. (PRWEB) , ... October 13, 2015 ... ... print media enterprise focused on cancer patients, today announced a new partnership with ... for patients battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ... study has shown that women who successfully lose weight with a bariatric procedure are ... States each year. The article notes that anywhere from 40 to 50 percent of ...
(Date:10/13/2015)... ... , ... In an age where the cost of energy is rising, ... than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent ... percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is the ...
(Date:10/13/2015)... Nashville, Tenn. (PRWEB) , ... October 13, 2015 , ... ... life, and that’s why SmileCareClub , the leading remote invisible aligner system, has ... children who would otherwise go without it. For each aligner treatment plan purchased, SmileCareClub ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Scientists in Seattle ... biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted an ... The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia found ...
Breaking Medicine News(10 mins):